Exosome Research Market Analysis, Opportunity Forecasts Report 2026-2035 [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
Key growth is seen in non-invasive liquid biopsies and exosome-based delivery systems for drugs. North America leads in market share. Major players include Capricor and Lonza. Exosome Research Market Exosome Research Market · GlobeNewswire Inc. Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Exosome Research Market Analysis, Opportunity Forecasted For 2026-2035" has been added to ResearchAndMarkets.com's offering. The exosome research market is experiencing significant growth, marked by expanding commercial relevance and innovation. In 2025, the market was valued at approximately US$ 280.70 million and is projected to reach US$ 2.49 billion by 2035, growing at a CAGR of 24.4% over the forecast period. This evolution highlights the rising prominence of exosomes in biomedical research, diagnostics, and therapeutic development. One of the core catalysts for this shift is the accumulation of validated clinical efficacy data, which has bolstered confidence in exosomes as entiti
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual MeetingGlobeNewswire
- Top 10 Healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x [Seeking Alpha]Seeking Alpha
- Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? [Yahoo! Finance]Yahoo! Finance
- Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics (CAPR) had its price target raised by B. Riley Financial, Inc. from $50.00 to $63.00. They now have a "buy" rating on the stock.MarketBeat
CAPR
Earnings
- 3/12/26 - Miss
CAPR
Analyst Actions
- 3/10/26 - HC Wainwright
CAPR
Sec Filings
- 4/10/26 - Form ARS
- 4/10/26 - Form DEF
- 4/3/26 - Form 4
- CAPR's page on the SEC website